Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2026 Jun 8;17:1882446. doi: 10.3389/fphar.2026.1882446

Correction: EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer

Xiaomin Wang 1,2,3,†, Yuhang Ding 1,2,†, Yunxiao Mai 1,2,†, Ruinan Li 1, Xinyu Shao 3,4, Wenlong Chen 1,2, Yiming Li 1,2, Luhaoxiang Liu 1,2, Haoran Wang 1,2, Kangkang Liu 2, Yuanjie Niu 2,5, Jianmin Li 2, Guoping Xu 1,*, Yang Zhao 1,2,*
PMCID: PMC13284464  PMID: 42338971

There was a mistake in Figure 6 as published. The incorrect image was used. The corrected Figure 6 appears below.

FIGURE 6.

Panel A shows a transmission electron microscopy image of TAZ-Lip nanoparticles with a 100 nanometer scale bar. Panel B presents a histogram of TAZ-Lip nanoparticle diameter distribution, showing most particles near 69 nanometers with a polydispersity index of 0.19. Panel C displays a transmission electron microscopy image of DOX-Lip nanoparticles, also with a 100 nanometer scale bar. Panel D shows a histogram of DOX-Lip nanoparticle diameter distribution, peaking near 80 nanometers, polydispersity index 0.19. Panel E features a scatter plot comparing zeta potential measurements between TAZ-Lip and DOX-Lip, both near minus 30 millivolts. Panel F depicts a line chart of polydispersity index for TAZ-Lip and DOX-Lip over seven days, showing stable values around 0.2 for both samples.

Characterization of TAZ/DOX-Lip nanoparticles. (A,C) TEM images of TAZ-Lip (A) and DOX-Lip (C), Scale bar: 100 nm. (B,D) Size distribution of TAZ-Lip (B) and DOX-Lip (D). (E) Zeta potentials of TAZ-Lip and DOX-Lip (n = 3). (F) PDI of TAZ-Lip and DOX-Lip NPs measured over 7 days (n = 3).

The original article has been updated.

Footnotes

Edited and reviewed by: Donato Colangelo, Università del Piemonte Orientale, Italy

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES